Rezolute is a late-stage rare disease biopharmaceutical company focused on developing transformative therapies for patients living with severe metabolic and endocrine disorders. Our mission is to bring hope and meaningful solutions to patients and families affected by rare and difficult-to-treat diseases through scientific innovation, collaboration, and integrity.

Rezolute’s lead investigational therapy, RZ358 (ersodetug), is a fully human monoclonal antibody in late-stage clinical development for the treatment of hypoglycemia due to congenital and acquired forms of hyperinsulinism (HI). As Rezolute expands its medical and scientific focus into tumor-related hyperinsulinism (tumor HI), most commonly related to pancreatic neuroendocrine tumors (insulinomas) or paraneoplastic hypoglycemia (NICTH), the company is committed to advancing novel therapeutic strategies that address this rare and complex form of hypoglycemia associated with insulin-secreting tumors and related neuro-oncology disorders.

Position Summary

We are seeking a dynamic and experienced Vice President of Commercial Operations to establish and lead all operational aspects of our commercial strategy in support of the launch of our first rare disease therapy. This includes managing commercial operations functions ensuring the infrastructure, processes, and strategies necessary for successful product launch. This individual will be a strategic and hands-on leader responsible for building and managing critical commercial infrastructure, including sales operations, analytics, forecasting, market access operations, and commercial systems. This role oversees sales operations, forecasting and analytics, incentive compensation, market research, data management, CRM systems, field effectiveness, and commercial training.

The ideal candidate has experience in rare disease or specialty pharmaceutical markets and thrives in an entrepreneurial, fast-paced environment. The ideal candidate has experience in rare disease or specialty pharmaceutical markets and thrives in an entrepreneurial, fast-paced environment.

This role is based in the home office and requires minimum of 3 days per week in the office.

Key Responsibilities

Serve as a key member of the Commercial Leadership Team, developing and executing commercial strategy and operations plans.
Develop and execute the commercial operations infrastructure to support a successful rare disease product launch.
Lead commercial planning processes, including sales forecasting, demand planning, incentive compensation design, and territory alignment.
Build and oversee a high-functioning sales operations team and associated systems (CRM, data warehousing, reporting dashboards).
Establish data governance processes and manage third-party vendors providing data (claims, specialty pharmacy, distribution).
Partner cross-functionally with Market Access, Marketing, Medical Affairs, Finance, and IT to ensure alignment of commercial operations with overall corporate goals.
Design and manage KPIs and reporting frameworks to track performance and inform commercial decision-making.
Lead field force enablement efforts, including CRM configuration, targeting, call planning, and field reporting.
Support the development of compliant policies and processes for commercial activities in collaboration with Legal and Compliance teams.
Manage operational budgets, contracts, and vendor relationships for commercial functions.

Qualifications:

Bachelor’s degree required; MBA or advanced degree preferred.
12+ years of progressive experience in commercial operations within the biopharmaceutical industry, including at least 5 years in a leadership role.
Direct experience supporting launch planning and execution for rare disease or specialty products.
Deep understanding of commercial data sources (e.g., specialty pharmacy, HUB services, patient services, claims data).
Demonstrated success in building commercial infrastructure in a high-growth or startup environment.
Strong project management skills, attention to detail, and ability to lead cross-functional initiatives.
Excellent communication and leadership skills with a collaborative approach.
Familiarity with compliance regulations in the rare disease space.

Preferred Attributes

Experience in both pre-commercial and commercial-stage biotech organizations.
Entrepreneurial mindset and comfort operating in a fast-paced, evolving environment.
Ability to work in a lean organization with a hands-on, roll-up-your-sleeves style.
Passion for serving patients with serious or underserved diseases.

Rezolute (RZLT) currently anticipates the base salary for the Vice President of Commercial Operations role could range from $300,000 to $360,000 and will depend, in part, on the successful candidate’s geographical location and their qualifications for the role, including education and experience. This position will also be eligible for an annual performance bonus in accordance with the terms of the applicable plan (depending, in part, on company and individual performance and at the Company’s discretion on an individual basis). The compensation described above is subject to change and could be higher or lower than the range described based on current market survey data and the qualifications, education, experience and geographical location of the selected candidate.

Qualifying employees are eligible to participate in benefit programs such as:

Health Insurance (Medical / Dental / Vision)
Disability, Life & Long-Term Care Insurance
Holiday Pay
Tracking Free Vacation Program
401(k) Plan Match
Educational Assistance Benefit
Fitness Center Reimbursement

We are an Equal Opportunity Employer and do not discriminate against applicants due to race, ethnicity, gender, veteran status, or on the basis of disability or any other federal, state or local protected class.

About the company

Rezolute Bio develops therapies for rare diseases, aiming to address unmet needs in both pediatric and adult patients. Its lead candidate, RZ358, is a human monoclonal antibody in late-stage trials for congenital hyperinsulinism and works by binding to and inhibiting insulin to reduce hypoglycemic events. The company also pursues RZ402, an oral plasma kallikrein inhibitor for diabetic macular edema. Its goal is to bring approved therapies to patients by advancing late-stage programs toward commercialization and building a portfolio focused on rare diseases.

Company Size

51-200

Company Stage

IPO

Headquarters

Louisville, Kentucky

Founded

2010

Get referred to Rezolute Bio

See people who can refer or advise you

Simplify's Take

What believers are saying

PES 2026 analyses showed CGM hypoglycemia reductions above 50% versus placebo.
FDA accepted tumor HI development streamlining in September 2025, with topline data expected 2H 2026.
Cash and investments reached $120.3 million on March 31, 2026, supporting runway.

What critics are saying

SunRIZE missed primary and key secondary endpoints in December 2025, damaging approval odds.
FDA requested broader sunRIZE and extension datasets on March 17, 2026, delaying filing.
A December 2025 layoff cut 29 employees after the setback, signaling fragile execution.

What makes Rezolute Bio unique

Ersodetug targets insulin receptor signaling, addressing congenital and tumor hyperinsulinism downstream.
FDA granted Breakthrough Therapy Designation for congenital HI on January 7, 2025.
Rezolute paired ersodetug with commercial hires from Ultragenyx and Cytokinetics in 2025.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance
Disability Insurance
Life Insurance
Paid Holidays
Paid Vacation
401(k) Plan Match
Gym Membership

Growth & Insights and Company News

Headcount

6 month growth

-5%

1 year growth

2 year growth

-1%

Africa Business Watch

Jul 21st, 2026

Rezolute to participate in the BTIG Virtual Biotechnology Conference.

Rezolute to participate in the BTIG Virtual Biotechnology Conference. REDWOOD CITY, Calif., July 21, 2026 (GLOBE NEWSWIRE) - Rezolute, Inc. (Nasdaq: RZLT) ("Rezolute" or the "Company"), a late-stage ultra-rare disease company focused on treating refractory hypoglycemia caused by a congenital or any acquired form of hyperinsulinism (HI), today announced that management will participate in the BTIG Virtual Biotechnology Conference, taking place July 28-29, 2026. Management will be participating in one-on-one investor meetings throughout the conference. Investors interested in scheduling a meeting with the Rezolute management team should contact their BTIG representative. About Rezolute, Inc. Rezolute is a late-stage ultra-rare disease company focused on treating refractory hypoglycemia caused by a congenital or any acquired form of hyperinsulinism (HI). The Company's antibody therapy, ersodetug, has been studied in clinical trials and used in real-world cases for the treatment of refractory hypoglycemia due to a variety of causes of HI. For more information, visit www.rezolutebio.com. Rezolute Contacts: Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

The Manila Times

Apr 21st, 2026

Rezolute to present results from its Phase 3 sunRIZE study in congenital hyperinsulinism at the Pediatric Endocrine Society (PES) Annual Meeting.

Rezolute to present results from its Phase 3 sunRIZE study in congenital hyperinsulinism at the Pediatric Endocrine Society (PES) Annual Meeting. By GlobeNewswire April 21, 2026 Oral presentation will include previously announced topline results as well as pre-specified and post-hoc data updates REDWOOD CITY, Calif., April 21, 2026 (GLOBE NEWSWIRE) - Rezolute, Inc. (Nasdaq: RZLT) ("Rezolute" or the "Company"), a late-stage rare disease company focused on treating hypoglycemia caused by all forms of hyperinsulinism (HI), today announced that results from the Phase 3 sunRIZE study of ersodetug in congenital HI were accepted for an oral presentation at the Pediatric Endocrine Society (PES) Annual Meeting being held April 30-May 3, 2026, in San Francisco, CA. In addition to the previously reported topline results, the presentation will also include results from pre-specified and post-hoc sunRIZE analyses, which the Company believes continue to demonstrate target engagement and the therapeutic benefit of ersodetug. Presentation Title: Top-Line Results From a Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study (sunRIZE) Format: Oral presentation Presenter: Diva D. De León-Crutchlow, MD, MSCE Session Date and Time: Friday, May 1, 2026, from 8:15 a.m. - 9:15 a.m. PT Session Title: Oral Abstracts #1 About sunRIZE The Phase 3 sunRIZE study (RZ358-301) was a multi-center, randomized, double-blind, placebo-controlled, parallel arm study designed to evaluate the efficacy and safety of ersodetug in patients with congenital hyperinsulinism (HI), ages 3 months to 45 years old, who were experiencing continued hypoglycemia on currently available standard of care (SOC). Eligible participants were randomized to one of three treatment arms to receive either ersodetug (5 or 10 mg/kg) or matched placebo-control as add on to existing SOC. Study drug was administered every other week during an initial loading phase, and then every 4 weeks during the 6-month controlled pivotal treatment period. Following the pivotal treatment phase of the study, participants could roll-over into an optional open-label extension phase to continue to receive ersodetug. The study enrolled 63 participants in more than a dozen countries around the world, inclusive of U.S. patients. The primary and key secondary efficacy endpoints in the study were the change from baseline in the average number of hypoglycemia events per week and the average percent time in hypoglycemia, respectively, over six months of treatment. About Ersodetug Ersodetug is a fully human monoclonal antibody that binds allosterically to the insulin receptor to decrease receptor over-activation by insulin and related substances (such as IGF-2) in the setting of hyperinsulinism (HI), thereby improving hypoglycemia. Because ersodetug acts downstream from the pancreas, it has the potential to be universally effective at treating hypoglycemia due to any congenital or acquired form of HI. About Rezolute, Inc. Rezolute is a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism (HI). The Company's antibody therapy, ersodetug, is designed to treat all forms of HI and has been studied in clinical trials and used in real-world cases for the treatment of both congenital and tumor HI. For more information, visit www.rezolutebio.com. Forward-Looking Statements This release, like many written and oral communications presented by Rezolute and our authorized officers, may contain certain forward-looking statements regarding our prospective performance and strategies within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 and are including this statement for purposes of said safe harbor provisions. Forward-looking statements, which are based on certain assumptions and describe future plans, strategies, and expectations of Rezolute, are generally identified by use of words such as "anticipate," "believe," "estimate," "expect," "intend," "plan," "project," "seek," "strive," "try," or future or conditional verbs such as "could," "may," "should," "will," "would," or similar expressions. These forward-looking statements include, but are not limited to, the potential efficacy of ersodetug in treating hypoglycemia. Our ability to predict results or the actual effects of our plans or strategies is inherently uncertain. Accordingly, actual results may differ materially from anticipated results. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Except as required by applicable law or regulation, Rezolute undertakes no obligation to update these forward-looking statements to reflect events or circumstances that occur after the date on which such statements were made. Important factors that may cause such a difference include any other factors discussed in our filings with the SEC, including the Risk Factors contained in Rezolute's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, which are available at the U.S. Securities and Exchange Commission's website at www.sec.gov. You are urged to consider these factors carefully in evaluating the forward-looking statements in this release and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by this cautionary statement. Rezolute Contacts: Christen Baglaneas 508-272-6717 Carrie McKim 336-608-9706

The Manila Times

Mar 4th, 2026

Rezolute to Participate in the Citizens Life Sciences Conference

Rezolute to participate in the Citizens Life Sciences Conference. By GlobeNewswire March 4, 2026 REDWOOD CITY, Calif., March 04, 2026 (GLOBE NEWSWIRE) - Rezolute, Inc. (Nasdaq: RZLT) ("Rezolute" or the "Company"), a late-stage rare disease company focused on treating hypoglycemia caused by all forms of hyperinsulinism (HI), today announced that management will participate in the Citizens Life Sciences Conference, taking place March 10-11, 2026, in Miami, FL. Management will be participating in one-on-one investor meetings throughout the conference. Investors interested in scheduling a meeting with the Rezolute management team should contact their Citizens representative. About Rezolute, Inc. Rezolute is a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism (HI). The Company's antibody therapy, ersodetug, is designed to treat all forms of HI and has been studied in clinical trials and used in real-world cases for the treatment of both congenital and tumor HI. For more information, visit www.rezolutebio.com. Rezolute Contacts: Christen Baglaneas 508-272-6717 Carrie McKim powered by 336-608-9706

Rezolute, Inc.

Feb 4th, 2026

Rezolute to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

Rezolute to participate in the Guggenheim Emerging Outlook: Biotech Summit 2026. February 04, 2026 7:00 am EST Download as PDF REDWOOD CITY, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) - Rezolute, Inc. (Nasdaq: RZLT) ("Rezolute" or the "Company"), a late-stage rare disease company focused on treating hypoglycemia caused by all forms of hyperinsulinism (HI), today announced that management will participate in the Guggenheim Emerging Outlook: Biotech Summit 2026, taking place February 11-12, 2026 in New York. Management will be participating in one-on-one investor meetings throughout the conference. Investors interested in scheduling a meeting with the Rezolute management team should contact their Guggenheim representative. Rezolute is a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism (HI). The Company's antibody therapy, ersodetug, is designed to treat all forms of HI and has been studied in clinical trials and used in real-world cases for the treatment of both congenital and tumor HI. For more information, visit www.rezolutebio.com. Released February 4, 2026

Fierce Pharma

Aug 21st, 2025

Rezolute resolves commercial question, hiring ex-Ultragenyx exec to ready for rare disease launch

Karnawat joins Rezolute from Cytokinetics, where he spent just over a year as vice president of global value, access and distribution.

Rezolute Bio

Vice President of Commercial Operations - Commercial Operations, Tumor HI Program

About the job